ReCODE® (Reversal of Cognitive Decline) is a precision medicine protocol developed by Dr. Dale Bredesen, MD, that takes a fundamentally different approach to cognitive decline and Alzheimer’s disease. Rather than relying on a single medication, ReCODE identifies and addresses the multiple biological contributors unique to each individual—including inflammation, insulin resistance, nutrient deficiencies, hormonal imbalances, toxic exposures, sleep disorders, infections, vascular health, and other modifiable factors.

​

This personalized approach is supported by a growing body of clinical research. Dr. Bredesen’s 2022 peer-reviewed trial demonstrated measurable improvements in cognition among participants receiving individualized treatment. More recently, the completed multicenter Evanthea randomized controlled trial found statistically significant improvements in memory, executive function, processing speed, and overall cognition compared with standard care, while also demonstrating improvements in important metabolic health markers. Together, these studies provide the strongest clinical evidence to date supporting a precision medicine approach to early cognitive decline.